星空体育官方入口网站网址大全-登录入口官网

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-06-24 123dc049m24(暂无昵称) 来自广东省

从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了

25 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-04-24 白衣13 来自伊利诺伊

求好运，编辑和审稿人一生平安！！！

Manuscript Under Consideration 11th Apr 24 05:59:46
Editor Assigned 10th Apr 24 04:50:35
Manuscript Received 10th Apr 24 04:50:34

29 18

展开18条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-02-19 ms5000001629270806 来自上海

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂

56 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-06-24 123dc049m24(暂无昵称) 来自广东省

从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了

25 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-06-25 36192448 来自湖南省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊

19 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2022-01-10 Pig1000

请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received

45 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-06-27 ms9000000424678117 来自山东省

请问要求未剪裁整膜，可以目的和内参不在一张膜吗

14 0

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-06-20 ms6000001702952186 来自河南省

偏重的研究方向：肿瘤转移;肿瘤生物学
经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈

31 0

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-05-09 ms4000000471597518 来自重庆

请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方

41 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211332, encodeId=4a2e221133255, content=从大CDD转过来，从Under Consideration 9天直接变成了Decision Made，是不是完全没戏了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:36:13 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2200214, encodeId=241d2200214d6, content=求好运，编辑和审稿人一生平安！！！ Manuscript Under Consideration 11th Apr 24 05:59:46 Editor Assigned 10th Apr 24 04:50:35 Manuscript Received 10th Apr 24 04:50:34, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230127/dd490db5809c41dba47efd8445d736af/b6403d79e2fb4308b2f2b14ee7a06741.jpg, createdBy=1f234693702, createdName=白衣13, createdTime=Wed Apr 24 22:07:15 CST 2024, time=2024-04-24, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2188162, encodeId=a0a321881622b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：Cddise转投过来的，9天decision made，不知道是什么结果，这也太快了吧😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79419039130, createdName=ms5000001629270806, createdTime=Mon Feb 19 16:18:33 CST 2024, time=2024-02-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2211331, encodeId=37242211331bd, content=从大CDD转过来的，Under Consideration9天就变成了Decision Made，是不是没戏直接悲剧了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d52443072, createdName=123dc049m24(暂无昵称), createdTime=Mon Jun 24 10:34:44 CST 2024, time=2024-06-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2211626, encodeId=cafa221162697, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：给大家参考下：3.18号投稿，40天审完，一个月返修后5天，6.15号接收，6.25号见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Tue Jun 25 20:10:32 CST 2024, time=2024-06-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1182903, encodeId=2b621182903a8, content=请问各位，原则性接收上传最终稿后，走的流程还会不会有under consideration，现在上传已经4天了，还是manuscript received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Mon Jan 10 18:12:03 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2211975, encodeId=1b8322119e522, content=请问要求未剪裁整膜，可以目的和内参不在一张膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f09193690, createdName=ms9000000424678117, createdTime=Thu Jun 27 19:13:21 CST 2024, time=2024-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210907, encodeId=af9f221090ee3, content=偏重的研究方向：肿瘤转移;肿瘤生物学 经验分享：哈哈哈哈！以前投的Q2，今天升Q1了哈哈哈哈哈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Thu Jun 20 23:09:49 CST 2024, time=2024-06-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2203732, encodeId=e3e72203e32b5, content=请问修改后的版本要怎么上传呢，我看邮件链接里没有可以上传修订后版本的地方, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe18212751, createdName=ms4000000471597518, createdTime=Thu May 09 20:49:01 CST 2024, time=2024-05-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2208362, encodeId=4d612208362d2, content=偏重的研究方向：机制 经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Wed Jun 05 06:09:13 CST 2024, time=2024-06-05, status=1, ipAttribution=湖北省)]

2024-06-05 ms3000000526945160 来自湖北省

偏重的研究方向：机制
经验分享：大家一般投稿后多久才送审啊？我的已经投了7天了，还在编辑那里

35 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务